[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363315-105":59,"doc-detail-363315-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","efficacy-of-intraoperative-use-of-20-albumin-in-combination-with-ringers-lactate-versus-ringers-lactate-protocol-for-a-randomised-controlled-open-label-clinical-trial-albuchip-trial","Efficacy of Intraoperative Use of 20% Albumin in Combination with Ringer’s Lactate versus Ringer’s Lactate - Protocol for a Randomised Controlled, Open-label Clinical Trial (ALBUCHIP trial)","","Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is standard for peritoneal metastases, yet it involves major intraoperative fluid shifts and endothelial permeability that can lead to adverse perioperative outcomes. Albumin has shown value as an intravenous fluid in critically ill patients, but evidence for major noncardiac surgery requiring substantial fluids remains limited. The ALBUCHIP trial evaluates 20% albumin plus Ringer’s lactate versus Ringer’s lactate alone for postoperative outcomes in CRS with HIPEC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/efficacy-of-intraoperative-use-of-20-albumin-in-combination-with-ringers-lactate-versus-ringers-lactate-protocol-for-a-randomised-controlled-open-label-clinical-trial-albuchip-trial/363315/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/efficacy-of-intraoperative-use-of-20-albumin-in-combination-with-ringers-lactate-versus-ringers-lactate-protocol-for-a-randomised-controlled-open-label-clinical-trial-albuchip-trial/363315.png","ImageObject",300,407,{"name":92,"@type":93},"Stanford","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the ALBUCHIP trial?","Question",{"text":112,"@type":113},"To evaluate the efficacy of 20% albumin combined with Ringer’s lactate versus Ringer’s lactate alone for fluid therapy during CRS with HIPEC, focusing on postoperative outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How are participants assigned to study groups?",{"text":117,"@type":113},"Eligible patients undergoing CRS with HIPEC are randomly assigned in a 1:1 ratio to control (Ringer’s lactate) or intervention (20% albumin + Ringer’s lactate), stratified by centre.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the primary outcome measure?",{"text":121,"@type":113},"The primary outcome is the Comprehensive Complication Index (CCI) score at day 28 after CRS with HIPEC.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363315,1790179379,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Open access Protocol  \nTo cite: Deniau B, Moreau A, Monsel A, et al. Efficacy of intraoperative use of 20% albumin in combination with Ringer’s lactate versus Ringer’s lactate during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy:  \nprotocol for a randomised controlled, open-label clinical trial (ALBUCHIP trial) . BMJ Open 2026;16:e109391 . doi:10 . 1136/ bmjopen-2025-109391  \n► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[bmjopen-2025-109391](bmjopen-2025-109391)) .  \nReceived 14 August 2025 Accepted 27 March 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Benjamin Deniau; [benjdeniau@gmail.com](benjdeniau@gmail.com)  \nEfficacy of intraoperative use of 20% albumin in combination with Ringer’s lactate versus Ringer’s lactate during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: protocol for a randomised controlled, open-label clinical trial (ALBUCHIP trial)  \nBenjamin Deniau  ,1,2,3,4,5 Arthur Moreau,1,3,5 Antoine Monsel,6,7,8 Valentina Faitot,9 Julien Pottecher,9,10 Lana Zoric,11 Stéphanie Suria,12 Ezechiel Bankole,13 Daphné Michelet,13,14 Nathalie Poirier,1 Benoit Plaud,1,3,5,15 Clotilde Chaix,16 Lucie Biard,16 Francois Depret1,3,4,5  \nABSTRACT  \nIntroduction Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is considered the standard of care for the treatment of peritoneal metastases from gastrointestinal and gynaecological cancers. Characterised by substantial intraoperative fluid shifts and increased endothelial permeability, this procedure is associated with adverse perioperative outcomes. Human albumin has been extensively studied in critically ill patients as an intravenous fluid, but its efficacy during major noncardiac surgery involving substantial fluid requirements remains insufficiently evaluated. The aim of this trial is to evaluate the efficacy of 20% albumin in combination with Ringer’s lactate versus Ringer’s lactate alone for fluid therapy during CRS with HIPEC in relation to postoperative outcomes.  \nMethods and analysis The study protocol was designed and written in accordance with the Prospective Randomised Open, Blinded Endpoint design and followed the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) recommendations. This is a randomised controlled, open-label parallel-group multicentre clinical trial. Participants will be patients admitted for CRS with HIPEC. Eligible patients will be randomly assigned to either the control group (Ringer’s lactate) or the intervention group (20% albumin+Ringer’s lactate) in a 1:1 ratio, with stratification by centre. The primary outcome is the Comprehensive Complication Index (CCI) score at day 28 following CRS with HIPEC. Secondary endpoints include mortality at day 28, CCI score at day 7, volume of intraoperative and postoperative (48 hours) fluid therapy, cumulative incidence of surgical and medical postoperative complications, and number of days alive  \nSTRENGTHS AND LIMITATIONS OF THIS STUDY   \n⇒ The ALBUCHIP trial is one of the first trials to evaluate the efficacy of combining 20% albumin with Ringer’s lactate in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.  \n⇒ The ALBUCHIP trial is an open-label study with blinded evaluation of the primary outcome.  \n⇒ The number of enrolled patients is limited (130 participants recruited in France), which may reduce its external validity.  \nand out of the hospital by day 28. To ensure 90% power, a total of 140 patients (70 per group) are required to detect a 13 .6-point reduction in the CCI score on day 28 in the intervention group, assumin","cbCairZgU4H82r9z","https://ap.wps.com/l/cbCairZgU4H82r9z","pdf",468954,"English","# Abstract\n## Introduction\n## Methods and analysis\n## Strengths and limitations of this study\n## Ethics and dissemination\n# Trial registration","[{\"question\":\"What is the main goal of the ALBUCHIP trial?\",\"answer\":\"To evaluate the efficacy of 20% albumin combined with Ringer’s lactate versus Ringer’s lactate alone for fluid therapy during CRS with HIPEC, focusing on postoperative outcomes.\"},{\"question\":\"How are participants assigned to study groups?\",\"answer\":\"Eligible patients undergoing CRS with HIPEC are randomly assigned in a 1:1 ratio to control (Ringer’s lactate) or intervention (20% albumin + Ringer’s lactate), stratified by centre.\"},{\"question\":\"What is the primary outcome measure?\",\"answer\":\"The primary outcome is the Comprehensive Complication Index (CCI) score at day 28 after CRS with HIPEC.\"}]","Efficacy of Intraoperative Use of 20% Albumin in Combination with Ringer’s Lactate versus Ringer’s Lactate - Protocol for a Randomised Controlled, Open-label Clinical Trial (ALBUCHIP trial) | PDF",1790150792,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0633daf516d0b9a8a4fb0a0f47332ae5.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b0a9fc18be0bfe6f469b8bb537d73de.webp",982,1309,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e775e6edfdd1b53be8a29ef5dcb92f50.webp",981,1308,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c075d7f3c74ee145b763fff74a591a4.webp",980,1306]